Soluble CD14 subtype (sCD14-ST) is a biomarker for neonatal sepsis

Liping Chen; Ting Xiao; Yan Luo; Qunfeng Qiu; Rongliang Que; Xiaohua Huang; Dingchang Wu

Soluble CD14 subtype (sCD14-ST) is a biomarker for neonatal sepsis

Int J Clin Exp Pathol. 2017 Sep 1;10(9):9718-9724. eCollection 2017.

Authors

Liping Chen¹, Ting Xiao¹, Yan Luo², Qunfeng Qiu¹, Rongliang Que¹, Xiaohua Huang¹, Dingchang Wu¹

Affiliations

¹ Department of Clinical Laboratory, Fujian Longyan First Hospital, Longyan First Affiliated Hospital of Fujian Medical University Longyan 364000, Fujian, China.
² Department of Neonatology, Fujian Longyan First Hospital, Longyan First Affiliated Hospital of Fujian Medical University Longyan 364000, Fujian, China.

PMID: 31966854
PMCID: PMC6965933

Abstract

This prospective observational study evaluated soluble CD14 subtype (sCD14-ST) as an early diagnosis and monitoring biomarker for neonatal sepsis in controls, patients with sepsis, or systemic inflammatory response syndrome (SIRS). sCD14-ST, procalcitonin (PCT), C-reactive protein (CRP), white blood cell (WBC), and acute physiology and chronic health evaluation II (APACHE-II) score were evaluated before and after therapy. sCD14-ST levels were significantly higher in sepsis than in SIRS, and higher in SIRS than controls. Treatment significantly decreased sCD14-ST, APACHE-II, PCT, CRP, and WBC. sCD14-ST levels correlated with APACHE-II before and after therapy, and with PCT before therapy (r=0.201, P=0.05). The receiver operating characteristic area under the curve of sCD14-ST was 0.958. A 304.5 pg/mL cutoff value was associated with 95.8% sensitivity and 84.9% specificity. sCD14-ST had superior diagnostic power for neonatal sepsis than the other indicators. In conclusion, sCD14-ST is a potential biomarker for the early diagnosis and monitoring of neonatal sepsis.

Keywords: Sepsis; newborn; soluble CD14 subtype; systemic inflammatory response syndrome.